COVID-19: Medicago, vaccine clinical trial start: plant virus-like particles (VLP)
COVID-19:
Mitsubishi Tanabe Pharma: Medicago
On July 15, it was announced that Medicago, a Canadian subsidiary, has started Phase I clinical trial (P1 study) of the novel coronavirus vaccine.
It is a vaccine using plant-like virus-like particles (VLP).
Virus-like particle (VLP) vaccine:
We will also compare two types of adjuvants (immunity enhancers) introduced from other companies and examine the most promising administration method.
Looking at the results, we plan to start the P2/3 test in October.
P1 test:
In the P1 trial that started overseas, the first case was vaccinated.
Divide into three dose groups and inoculate twice to evaluate safety and immunogenicity.
180 healthy adults aged 18 to 55 will be registered.
Adjuvants from two companies:
The optimal vaccines will be examined by adding the adjuvants of GlaxoSmithKline and Dynavacs, which have recently been affiliated with each other.
If it goes smoothly, it is expected to be put to practical use in the first half of next year.
Chemical Daily
https://www.chemicaldaily.co.jp/
Initiatives Against COVID-19 in Canada
– Initiated Phase 1 Clinical Trials of VLP Vaccine Candidate
https://www.mt-pharma.co.jp/e/release/nr/2020/pdf/e_MTPC200715.pdf